PSK Pharma, a resident of Dubna Special Economic Zone (SEZ), will complete the construction of its biopharmaceutical manufacturing facility at the end of 2018. The facility is expected to produce more than 30 medicinal products.
The project provides for manufacturing a wide range of high-tech medicinal products, including biosimilars, medicines for the treatment of asthma and chronic obstructive pulmonary diseases, etc. The company’s products can substitute imports and are included in the list of vital and essential drugs under the PHARMA 2020 strategy for the development of pharmaceutical industry.
“We firmly believe that, in the current global scenario, the availability of medicines for patients is a necessity, and we can do it without compromising on the product quality,” said Satya Karm Punia, President of Rus Biofarm LLC and founder of PSK Pharma LLC who initiated the project.
This will be confirmed by the fact that products manufactured in the pharmaceutical plant of Dubna Special Economic Zone will be affordable while meeting all global standards.
After reaching its full capacity, the plant is ready to substitute a significant share in the relevant segment of medicinal products on the Russian market. Overall, the resident of Dubna SEZ plans to invest at least 1.7 billion rubles in the implementation of the project.